mingwan0, I'll stand in the corner, if you will explain the math to the good folks on this board.
DNAP has 'promised' to buy $25 million dollars worth of Biofrontera. They will use money that they get for the sale of their unreleased stock. The transaction will begin as soon as they register the stock.
Here's my problem. The current capitalized value of DNAP [750 Million shares at (generously) 2 cents apiece] is about $15 million dollars. If they release every share they have left, [another 750 million shares] that $15 million will be diluted 50% and each share will be worth a penny. So at face value (not including the inevitable discount to the VC company) the sum total of releasable shares is worth at most $7.5 million dollars.
So explain how DNAP is going to obtain $25 million dollars in exchange for $7.5 million worth of shares. If they can't then the deal CANNOT occur as reported, and the PR is nothing but the latest in a long line of misrepresentations that goes back to the incestuous GMED 'deal'.
Anxiously waiting your response, [in the corner]
regards,
frog
News 
Market Data 
Discover 
